NRx 10-Q: Q3 Loss Narrows to $2.2M, But Going-Concern Doubt Persists
NRXP sits 78% above its 52-week low of $1.62 on elevated volume (2.0× avg).
Summary
NRx's Q3 10-Q shows the net loss narrowing to $2.2 million from $5.9 million and cash up to $19.8 million, but management formally states substantial doubt about the company's ability to continue as a going concern over the next twelve months.
Key Events · Earnings and Guidance · NRXP
-
Going-Concern Doubt Reiterated
Management concluded that substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the filing date, citing recurring operating losses and negative operating cash flow.
-
Q3 Loss Narrows Sharply
Q3 2026 net loss was $2.2 million, or $0.05 per share, versus $5.9 million, or $0.27 per share, a year earlier; nine-month net loss was $20.1 million versus $29.0 million.
-
Cash Position Improves to $19.8M
Cash and equivalents rose to $19.8 million from $7.8 million at December 31, 2025, funded by $20.7 million net from the June underwritten offering and $11.8 million of ATM proceeds; working capital deficit was $7.0 million.
-
DARPA Cash Milestones in Motion
The $11.2 million DARPA SPARC-TMS contract has $6.7 million obligated; the first two milestones were invoiced at roughly $2.2 million and Milestone 3 is about 75% complete, with a ~$3.4 million invoice expected in Q4 2026.
Analysis · NRXP · Life Sciences
The headline numbers were pre-released on November 17, but the formal 10-Q carries the going-concern conclusion: management states substantial doubt exists about the company's ability to continue as a going concern for at least twelve months. That is the fact that matters here. The balance sheet has improved — $19.8 million of cash versus $7.8 million at year-end, and the stockholders' deficit narrowed to $2.0 million from $15.9 million — largely on the back of the June underwritten offering ($20.7 million net) and $11.8 million of ATM proceeds. But the company still burned $19.9 million in operations over nine months and carries a $7.0 million working capital deficit, so the runway depends on the ketamine launch and DARPA cash actually arriving. The DARPA contract is worth up to $11.2 million with $6.7 million obligated; roughly $2.2 million of invoices are submitted and another ~$3.4 million is expected in Q4, which is non-dilutive money the company needs. Until commercial ketamine sales ramp — shipments are targeted for early January 2027 — the ATM remains the funding backstop, and that means continued dilution.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRXP was trading at $2.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.1M. The 52-week trading range was $1.62 to $5.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.